ABSTRACT OBJECTIVES This study sought to determine whether there is an ideal level of platelet reactivity (PR) to optimize safety and efficacy within the large multicenter ADAPT-DES (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents) study of 8,582 patients receiving successful drug-eluting stent implantation.
permitted the real-time assessment of antiplatelet effects, and high platelet reactivity (HPR) on clopidogrel has been associated with adverse ischemic events in numerous previous studies (1) (2) (3) (4) (5) (6) . Although ischemic events such as stent thrombosis (ST) and myocardial infarction (MI) have been strongly associated with subsequent mortality, the association between HPR and overall mortality has been weaker, perhaps due to more frequent major hemorrhagic complications with effective P2Y 12 receptor inhibition (7) (8) (9) (10) . In recognition of these counterbalancing effects, the concept of a "therapeutic window" has been proposed, representing the optimal level of platelet inhibition to suppress ischemic complications without causing excessive bleeding, as described from unadjusted analyses from small-to modest-sized observational studies (8) (9) (10) (11) . These studies did not, however, adjust for differences in baseline demographic, laboratory, and angiographic characteristics that may confound the interpretation of relative event rates between PR strata. 
METHODS
The study design, protocol, and primary results of the ADAPT-DES study have been previously described in detail (7) . In brief, ADAPT-DES was a large, prospective, multicenter registry specifically designed to determine the relationships among PRU and subsequent clinical events in patients treated with aspirin and clopidogrel undergoing successful coronary DES implantation. A total of 8,582 patients undergoing PCI with at least 1 DES who were adequately loaded with aspirin and clopidogrel were enrolled at 11 hospitals in the United States and Germany and were followed clinically for 2 years.
Adenosine diphosphate receptor platelet function testing was performed using the VerifyNow P2Y12 Table 4 and Online Table 1 ) were entered into multivariable Cox proportional hazards regression models for ST, clinically relevant bleeding, and all-cause mortality at 2 years. Multivariable models were built by stepwise variable selection with entry and exit criteria set at the p ¼ 0.10 level. For multivariable analyses assessing the independent association of PR with outcomes, the first (lowest) quintile of PRU was used as the referent category. In sensitivity analyses, the second quintile of PRU (PRU 95 to 159) was used as the referent category to examine whether there was an optimal "window" of antiplatelet effect. All p values are 2-tailed; a p value <0.05 was considered statistically significant. Statistical analyses were performed using SAS (version 9.1.3, SAS Institute, Cary, North Carolina).
RESULTS
The mean PRU was 188 AE 97 ( Figure 1 Patients with higher PRU were older, more likely to be female, and had higher body mass indices ( Table 1) .
Patients with higher PRU had a greater prevalence of comorbidities, including diabetes mellitus, hypertension, congestive heart failure, previous revascularization, and renal insufficiency. However, current smoking was less likely as PRU increased. Clinical presentation with ACS was also more prevalent with greater PRU. Baseline hemoglobin levels were lower among patients in the highest PRU quintiles, as was creatinine clearance. Platelet counts were highest among patients with the lowest PRU and relatively similar across the other PRU quintiles.
Angiographic and procedural characteristics were mostly similar across the PRU quintiles with the exception of lower left ventricular ejection fraction (and higher left ventricular end-diastolic pressure) as well as slightly fewer stents (and lower total stent length) among patients in the higher PRU quintiles ( Table 2) .
UNADJUSTED CLINICAL OUTCOMES. There was a monotonic increase in the incidence of definite/ probable ST from 0.7% to 1.8% across quintiles of PRU (p ¼ 0.025) (Table 3, Figure 2A ). The incidence of MI was similar in the lower 3 quintiles, and increasingly higher in the 2 highest PRU quintiles (p ¼ 0.001) ( Table 3) . Conversely, the rate of clinically relevant bleeding was highest among patients in the lowest PRU quintile (11.2%), and relatively constant across the 4 higher PRU quintiles (p ¼ 0.006) (Table 3, Figure 2B ). This finding was consistently observed for both in-hospital and out-of-hospital bleeding.
Finally, in this unadjusted analysis, all-cause mortality monotonically increased with higher PRU quintiles and was highest in the highest PRU quintile (p ¼ 0.006) (Table 3, Figure 2C ). Table 4) . Values are mean AE SD or n (%).
PRU ¼ P2Y12 reaction units.
Kirtane et al. Values are n (%).
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0.72 to 1.60; p ¼ 0.72). These findings were mirrored when the sample was restricted to patients with ACS (Online Table 1 ). Although the second quintile of PR appeared to optimize the balance between both bleeding and ST risk ( Figure 3A) , in sensitivity analyses, the hazards of overall mortality were consistent (and not significantly different from unity) across all PRU quintiles when compared with Q2 as the referent group ( Figure 3B ).
DISCUSSION
The principal findings from the present analysis of (17, 18) . In the present analysis, however, a relationship between increasing PRU and mortality was observed only in unadjusted analyses and not after multivariable adjustment for differences in baseline and procedural characteristics between patients with high versus low PR. There are several possible explanations for this discordance.
Although the lack of a significant correlation between PRU and mortality admittedly could be due to lack of power, with nearly 8,500 studied patients, the absence of even a trend toward an increase in the hazard of mortality across quintiles of PRU (Table 4) suggests that there are other influences upon overall mortality than PRU alone. For example, comorbidities that correlate with elevated PRU (e.g., diabetes, ACS, and greater extent of atherosclerosis) are likely stronger contributors to mortality risk than is PRU alone.
Another possible explanation for the lack of an independent relationship between PRU and mortality in the present study is the offsetting effects of bleeding and ischemia. In addition to reducing ST and MI, randomized trials have shown that greater inhibition of the platelet P2Y 12 receptor also results in increased hemorrhagic complications (17) (18) (19) . The present and previous studies have now clearly documented an association between profound inhibition of PRU and bleeding events (7,9,20,21), which in numerous studies have also been found to strongly correlate with subsequent mortality (22) (23) (24) .
These observations have led to the desire to search for an optimal "therapeutic window" of antiplatelet effect-one in which PR is low enough to prevent ischemic events, but not so low as to predispose to bleeding (8) (9) (10) (11) . In the present study, after multivariable adjustment for differences in baseline and procedural risk, patients in the lowest quintile of PR (those with PRU <95) were at the greatest risk for both in-hospital as well as out-of-hospital bleeding events following DES implantation, but at the least risk for ST. However, whereas ST rates steadily increased with increasing PRU, the hazard of bleeding within the 4 higher PRU quintiles was similar. As a result, these adjusted observations potentially identify an optimal therapeutic window of effect at levels of moderately inhibited PRU (Q2) to minimize ST without inordinately increasing clinically relevant bleeding. Previous groups have identified potentially different PRU cutoffs for the optimal window of antiplatelet effect (11) . Variability in the identification of an optimal window of antiplatelet effect could be due to study-specific differences including the ana- ADAPT-DES is the first study large enough to apply multivariable modeling across PR subgroups and thus affords novel insights into not only the optimal PRU range to maximize the difference between ischemia and bleeding, but also to the expected net benefit on overall patient outcomes. In this regard, the present analysis is also notable in highlighting the differences in findings from unadjusted versus adjusted analyses.
The fact that univariable analyses demonstrated greater mortality with increasing PRU suggests that this readily available test may be used as a biomarker to predict future risk (similar to more traditional risk factors such as advanced age and diabetes). However, the absence of an independent relationship between PRU and mortality suggests that currently available potent antiplatelet therapies capable of lowering PR would not be expected to reduce all-cause mortality, despite a potentially favorable effect on ST (notwithstanding non-platelet-related "off-target" effects of some of these agents) (18) .
STUDY LIMITATIONS. Despite multivariable adjustment, it is possible that unmeasured confounders could explain some of the observed findings from the present nonrandomized study. Although ADAPT-DES 
CONCLUSIONS
In this large, prospective observational study of DEStreated patients, increasing PR on clopidogrel was associated with increasing 2-year rates of ST in a monotonic fashion, whereas bleeding risk was confined to patients in the lowest PR quintile (PRU <95). This observation suggests that suppression of ST while minimizing the risk of bleeding with greater P2Y 12 receptor platelet inhibition may be optimized in DES-treated patients within a therapeutic VerifyNow PRU window of moderately inhibited PRU.
However, there was no demonstrable threshold effect of PRU for all-cause mortality in adjusted analyses, suggesting that targeting PR to a specific window would not be expected to substantially affect the overall rates of death.
PERSPECTIVES
WHAT IS KNOWN? HPR has been associated with adverse ischemic events among patients undergoing PCI.
WHAT IS NEW?
In this large multicenter registry study of 8,582 patients, HPR remained associated with adverse ischemic events among PCI patients, but low PR was associated with increased bleeding events, lending credence to the concept of an optimal therapeutic window of antiplatelet effect.
WHAT IS NEXT? Whether personalizing antiplatelet effects to balance the offsetting risks of ischemic and bleeding events can optimize overall outcomes for PCI patients remains to be shown prospectively, but there has been a renewed interest in this approach with the more widespread availability of more potent oral antiplatelet therapies, particularly in the context of the increasing complexity of current day PCI.
